← Back to patent-cliff list
CAS 106-95-6
3-bromoprop-1-ene1-Bromo-2-propene
Codes：MRIO-001、MRIO-002、DOLU-016、LEVO-021、PRUC-025、Atorvastatin-157、IXAB-054
Application context (from source-drug indications)
糖尿病神经病变苯磺酸美洛加巴林疱疹后神经痛苯磺酸美洛加巴林周围神经系统疾病苯磺酸美洛加巴林HIV感染多替拉韦钠分娩多替拉韦钠结核分枝杆菌感染多替拉韦钠肝炎多替拉韦钠疱疹病毒感染多替拉韦钠肝功能衰退多替拉韦钠重度抑郁症盐酸左米那普仑缺血性卒中盐酸左米那普仑抑郁盐酸左米那普仑便秘琥珀酸普芦卡必利术后并发症琥珀酸普芦卡必利肠内喂养不耐受琥珀酸普芦卡必利阿片类药物引起的便秘琥珀酸普芦卡必利疼痛琥珀酸普芦卡必利假性肠梗阻琥珀酸普芦卡必利高脂血症阿托伐他汀锶蛛网膜下腔出血阿托伐他汀锶高血压阿托伐他汀锶乳腺癌伊沙匹隆转移性乳腺癌伊沙匹隆宫颈癌伊沙匹隆前列腺癌伊沙匹隆实体瘤伊沙匹隆中性粒细胞减少伊沙匹隆
Source drugs (routes using this intermediate)
| Drug | Tier | Expiry |
|---|---|---|
| 苯磺酸美洛加巴林Mirogabalin besilate | Tier C — Watch / trade | 2030 |
| 多替拉韦钠Dolutegravir Sodium | Tier B — Position early | - |
| 盐酸左米那普仑Levomilnacipran Hydrochloride | Tier C — Watch / trade | - |
| 琥珀酸普芦卡必利Prucalopride Succinate | Tier C — Watch / trade | - |
| 阿托伐他汀锶Atorvastatin strontium | Tier C — Watch / trade | - |
| 伊沙匹隆Ixabepilone | Tier C — Watch / trade | - |
Position in synthesis routes (up/downstream chain)
Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.
3-bromoprop-1-ene→3-bromoprop-1-ene→ethyl 4-ethyl-3-hydroxyhept-6-enoate→4-ethyl-3-hydroxyhept-6-enoic acid→tert-butyl 2-(dimethoxyphosphoryl)acetate→(E)-tert-butyl 2-(3-ethylbicyclo[3.2.0]hept-3-en-6-ylidene)acetate→tert-butyl 2-(3-ethyl-6-(nitromethyl)bicyclo[3.2.0]hept-3-en-6-yl)acetate→tert-butyl 2-((1R,5S,6S)-3-ethyl-6-(nitromethyl)bicyclo[3.2.0]hept-3-en-6-yl)acetate→tert-butyl 2-((1R,5S,6S)-6-(((tert-butoxycarbonyl)amino)methyl)-3-ethylbicyclo[3.2.0]hept-3-en-6-yl)acetate
3-hydroxy-2-methyl-4H-pyran-4-one→3-(benzyloxy)-2-methyl-4H-pyran-4-one→3-(benzyloxy)-2-methylpyridin-4(1H)-one→3-(benzyloxy)-5-bromo-2-methylpyridin-4-ol→methyl 5-(benzyloxy)-4-hydroxy-6-methylnicotinate→methyl 4-acetoxy-5-(benzyloxy)-6-methylnicotinate→4-acetoxy-3-(benzyloxy)-5-(methoxycarbonyl)-2-methylpyridine 1-oxide→methyl 4-acetoxy-6-(acetoxymethyl)-5-(benzyloxy)nicotinate→6-(acetoxymethyl)-5-(benzyloxy)-4-oxo-1,4-dihydropyridine-3-carboxylic acid→(2,4-difluorophenyl)methanamine→5-(benzyloxy)-N-(2,4-difluorobenzyl)-6-(hydroxymethyl)-4-oxo-1,4-dihydropyridine-3-carboxamide→5-(benzyloxy)-N-(2,4-difluorobenzyl)-6-formyl-4-oxo-1,4-dihydropyridine-3-carboxamide→3-(benzyloxy)-5-((2,4-difluorobenzyl)carbamoyl)-4-oxo-1,4-dihydropyridine-2-carboxylic acid→methyl 3-(benzyloxy)-5-((2,4-difluorobenzyl)carbamoyl)-4-oxo-1,4-dihydropyridine-2-carboxylate→methyl 3-(benzyloxy)-5-((2,4-difluorobenzyl)carbamoyl)-4-oxo-1,4-dihydropyridine-2-carboxylate→3-bromoprop-1-ene→methyl 1-allyl-3-(benzyloxy)-5-((2,4-difluorobenzyl)carbamoyl)-4-oxo-1,4-dihydropyridine-2-carboxylate→methyl 3-(benzyloxy)-5-((2,4-difluorobenzyl)carbamoyl)-4-oxo-1-(2-oxoethyl)-1,4-dihydropyridine-2-carboxylate→(R)-3-aminobutan-1-ol→(4R,12aS)-7-(benzyloxy)-N-(2,4-difluorobenzyl)-4-methyl-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2H-pyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxamide
4-amino-5-chloro-2,3-dihydrobenzofuran-7-carboxylic acid→1-(3-methoxypropyl)piperidin-4-amine→methyl 4-acetamido-2-hydroxybenzoate→methyl 4-acetamido-5-chloro-2,3-dihydrobenzofuran-7-carboxylate→3-bromoprop-1-ene→methyl 4-acetamido-2-(allyloxy)benzoate→methyl 4-acetamido-3-allyl-2-hydroxybenzoate→methyl 4-acetamido-2-hydroxy-3-(2-oxoethyl)benzoate→methyl 4-acetamido-2-hydroxy-3-(2-hydroxyethyl)benzoate→methyl 4-acetamido-2,3-dihydrobenzofuran-7-carboxylate
1,1-Dimethylethyl cyanoacetate→1-Bromo-2-propene→tert-Butyl 3-oxohex-5-enoate→tert-Butyl (3R)-3-hydroxyhex-5-enoate→tert-Butyl [(4R,6S)-6-(bromomethyl)-2-oxo-1,3-dioxan-4-yl]acetate→[(4S,6R)-6-[2-(tert-Butoxy)-2-oxoethyl]-2,2-dimethyl-1,3-dioxan-4-yl]methyl acetate→(4R,6S)-6-Hydroxymethyl-2,2-dimethyl-1,3-dioxane-4-acetic Acid 1,1-dimethylethyl ester
tert-butyl (S,E)-(2-methyl-1-(2-methylthiazol-4-yl)-5-oxopent-1-en-3-yl)carbamate→(S,1E,5Z)-6-iodo-2-methyl-1-(2-methylthiazol-4-yl)hepta-1,5-dien-3-amine→(4S,7R,8S,9S,16S,Z)-4,8-dihydroxy-5,5,7,9,13-pentamethyl-16-((E)-1-(2-methylthiazol-4-yl)prop-1-en-2-yl)azacyclohexadec-13-ene-2,6-dione→1-((3aR,6R,7aS)-2,2-dioxidotetrahydro-3H-3a,6-methanobenzo[c]isothiazol-1(4H)-yl)ethan-1-one compound with ethane (1:1)→3,3-dimethylhexane-2,4-dione→(S)-1-((3aR,6R,7aS)-2,2-dioxidotetrahydro-3H-3a,6-methanobenzo[c]isothiazol-1(4H)-yl)-3-hydroxy-4,4-dimethylheptane-1,5-dione compound with ethane (1:1)→(S)-3-((tert-butyldimethylsilyl)oxy)-1-((3aR,6R,7aS)-2,2-dioxidotetrahydro-3H-3a,6-methanobenzo[c]isothiazol-1(4H)-yl)-4,4-dimethylheptane-1,5-dione compound with ethane (1:1)→(S)-2-methylpent-4-enal→(3S,6R,7S,8S)-3-((tert-butyldimethylsilyl)oxy)-1-((3aR,6R,7aS)-2,2-dioxidotetrahydro-3H-3a,6-methanobenzo[c]isothiazol-1(4H)-yl)-7-hydroxy-4,4,6,8-tetramethylundec-10-ene-1,5-dione compound with ethane (1:1)→(3S,6R,7S,8S)-3,7-bis((tert-butyldimethylsilyl)oxy)-1-((3aR,6R,7aS)-2,2-dioxidotetrahydro-3H-3a,6-methanobenzo[c]isothiazol-1(4H)-yl)-4,4,6,8-tetramethylundec-10-ene-1,5-dione compound with ethane (1:1)→tert-butyl ((S,1E,5Z)-6-iodo-2-methyl-1-(2-methylthiazol-4-yl)hepta-1,5-dien-3-yl)carbamate→tert-butyl ((1E,3S,5Z,10S,11S,12R,15S)-11,15-bis((tert-butyldimethylsilyl)oxy)-17-((3aR,6R,7aS)-2,2-dioxidotetrahydro-3H-3a,6-methanobenzo[c]isothiazol-1(4H)-yl)-2,6,10,12,14,14-hexamethyl-1-(2-methylthiazol-4-yl)-13,17-dioxoheptadeca-1,5-dien-3-yl)carbamate compound with ethane (1:1)→(3S,6R,7S,8S,12Z,15S,16E)-15-((tert-butoxycarbonyl)amino)-3,7-bis((tert-butyldimethylsilyl)oxy)-4,4,6,8,12,16-hexamethyl-17-(2-methylthiazol-4-yl)-5-oxoheptadeca-12,16-dienoic acid→(3S,6R,7S,8S,12Z,15S,16E)-15-amino-3,7-bis((tert-butyldimethylsilyl)oxy)-4,4,6,8,12,16-hexamethyl-17-(2-methylthiazol-4-yl)-5-oxoheptadeca-12,16-dienoic acid→(4S,7R,8S,9S,16S,Z)-4,8-bis((tert-butyldimethylsilyl)oxy)-5,5,7,9,13-pentamethyl-16-((E)-1-(2-methylthiazol-4-yl)prop-1-en-2-yl)azacyclohexadec-13-ene-2,6-dione→(E)-2-methyl-3-(2-methylthiazol-4-yl)acrylaldehyde→(R)-2-methylpropane-2-sulfinamide→(R)-2-methyl-N-((1E,2E)-2-methyl-3-(2-methylthiazol-4-yl)allylidene)propane-2-sulfinamide→3-bromoprop-1-ene→(R)-2-methyl-N-((S,E)-2-methyl-1-(2-methylthiazol-4-yl)hexa-1,5-dien-3-yl)propane-2-sulfinamide→(S,E)-2-methyl-1-(2-methylthiazol-4-yl)hexa-1,5-dien-3-amine→tert-butyl (S,E)-(2-methyl-1-(2-methylthiazol-4-yl)hexa-1,5-dien-3-yl)carbamate→tert-butyl ((3S,E)-5,6-dihydroxy-2-methyl-1-(2-methylthiazol-4-yl)hex-1-en-3-yl)carbamate
Intermediates available on this site
Side-by-side comparison of all listed offers on this CAS; price bands are list-price ranges, final price subject to RFQ confirmation.
| Supplier | Product | Price band | MOQ | Lead time | Qualifications |
|---|---|---|---|---|---|
| Qualified Partner — East China API Works | (1R,5S)-3-ethyl-Bicyclo[3.2.0]hept-3-en-6-one Pharmaceutical Intermediates | 询价 | 询价 | 询价 | — |
| Unibest Nantong cGMP Site | 3-ethylbicyclo[3.2.0]hept-3-en-6-one Pharmaceutical Intermediates | 询价 | 询价 | 询价 | — |
This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.